Comparative effectiveness of antitumour necrosis factor agents, biologics with an alternative mode of action and tofacitinib in an observational cohort of patients with rheumatoid arthritis in Switzerland

BACKGROUND: Multiple biologic and targeted synthetic disease-modifying rheumatic drugs (b/tsDMARDs) are approved for the management of rheumatoid arthritis (RA), including TNF inhibitors (TNFi), bDMARDs with other modes of action (bDMARD-OMA) and Janus kinase inhibitors (JAKi). Combination of b/tsDM...

Descripción completa

Detalles Bibliográficos
Autores principales: Finckh, A, Tellenbach, C, Herzog, L, Scherer, A, Moeller, B, Ciurea, A, von Muehlenen, I, Gabay, C, Kyburz, D, Brulhart, L, Müller, R, Hasler, P, Zufferey, P
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Rheumatoid Arthritis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7299517/
https://www.ncbi.nlm.nih.gov/pubmed/32385143
http://dx.doi.org/10.1136/rmdopen-2020-001174

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7299517/
https://www.ncbi.nlm.nih.gov/pubmed/32385143
http://dx.doi.org/10.1136/rmdopen-2020-001174

Ejemplares similares